Skip to main content

Table 1 Characteristics of patients achieving prolonged treatment-free remission and endoscopic healing following treatment (N = 10)

From: Profound remission in Crohn’s disease requiring no further treatment for 3–23 years: a case series

PatientAge, yearsSexPrior therapiesAMAT (Y/N)AMAT RegimenDuration of AMAT (years)Adjunct therapyDuration of treatment-free remission (years)
147MAzathioprineaNFMT methotrexate vitamin D4
221MPrednisone, right hemi-colectomyYRifabutin; clofazimine; clarithromycin, Ciprofloxacin, metronidazole1Anti-TNF infliximab infusion, vitamin D9
356FSulfasalazine; mesalazinea; azathioprinea; esomeprazole; Metronidazolea; Vancomycina.NFMT6
443MAzathioprinea; Mesalazinea; Esomeprazole.NFMT23
517FCiprofloxacina, metronidazolea, azathioprinea; PrednisoneYRifabutin; clofazimine; clarithromycin, ciprofloxacin, metronidazole and ethambutol9Infliximab18
648FMesalazineaYRifabutin; clofazimine; clarithromycin, ethambutol3FMT14
736FAdalimumab; Infliximab (alone); azathioprinea; ciprofloxacina; metronidazoleaYRifabutin; clofazimine; clarithromycin; metronidazole2FMT3
838FMesalazineaYRifabutin; clofazimine; clarithromycin, metronidazole, ciprofloxacin8Infliximab8
932FPrednisone; metronidazolea; ciprofloxacinaYRifabutin; clofazimine; clarithromycin, metronidazole, ciprofloxacin38
1016FMesalazinea; azathioprineaYRifabutin; clofazimine; clarithromycin, ethambutol8Infliximab11
  1. AMAT anti-mycobacterial antibiotic therapy, FMT faecal microbiota transplantation
  2. aTherapies known to have potential anti-MAP properties